Research and Markets has announced the addition of the "Global Pharmerging Markets 2017-2021" report to their offering.

The global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Novartis

Other prominent vendors

  • Abbott Laboratories
  • AbbVie
  • Alexion Pharmaceuticals
  • Allergan
  • Amgen
  • Aspen
  • Astellas Pharma
  • Baxter
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Eli Lilly
  • Takeda Pharma
  • Teva Pharmaceutical Industries
  • UCB
  • Valeant Pharmaceuticals
  • Others

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Global pharmaceutical market

Part 06: Road to pharmerging markets

Part 07: Pharmerging markets

Part 08: Market landscape

Part 09: Market segmentation by geography

Part 10: Market overview of tier I countries

Part 11: Market overview of tier II countries

Part 12: Market overview of tier III countries

Part 13: Market drivers

Part 14: Impact of drivers

Part 15: Market challenges

Part 16: Impact of drivers and challenges

Part 17: Market trends

Part 18: Vendor landscape

Part 19: Key vendor analysis

Part 20: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/sk9knv/global